Viral Vector Construction For mRNA Delivery

Gene therapy is a promising new approach for treating most cancers and genetic disorders through introducing foreign genomic substances into host cells to elicit a therapeutic benefit. The key to achievement of gene therapy is to create secure and efficient gene delivery vehicles. Viral vectors are the generally used carriers for delivering mRNA due to their high performance and safety. Seattle Genova offers comprehensive viral vectors and modern viral vector technology for fundamental research and preclinical applications, which includes the design and production of suitable viral vectors and small to large-scale manufacturing of viral vectors. Gene therapy, which delivers nucleic acid reagent into cells to regulate function in whole organism, is a promising therapeutic technique for most cancers and genetic diseases. The achievement of gene therapy commonly relies upon on delivery sufficient therapeutic reagents to the best target sites to attain the desired degree of therapeutic effects. The perfect state of affairs is to supply genetic substances into cells in a secure and high-efficient way to make it work.

Types of Seattle Genova’s viral vectors

All viruses bind to their hosts and introduce their genetic material into the host cell as a part of their replication cycle. However, most effective lysogenic viruses, which do now no longer kill cells quickly, have possibility to be modified as a vector. To be a delivery vector, viruses are required to be engineered for reducing the chance of virus-related toxicity. After modification, retroviruses, adenoviruses, even herpes simplex virus are potential vectors for gene delivery. Viral 

vectors can be divided into types: 

• Integrating viral vectors

• Non-integrating viral vectors. 

Integrated viral vectors can be integrated into the human genome, such as lentiviral, adeno-related virus and retroviral vectors. Non-integrating vectors, like adenoviral vectors, remain in the nucleus without being incorporated into the chromosomal DNA, hence the transgene is likely to lose at some point of cell division and the expression of foreign genes is transient.

Highlights

Deliverables

A viral vector construct for mRNA delivery

A complete work report.